#ViiV Healthcare

Each receives up to $200,000 thanks to ViiV Healthcare’s Positive Action for Youth program.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

The combo of Tivicay (dolutegravir) and Edurant (rilpivirine) showed comparable efficacy to three- and four-drug regimens in major trials.

An immersive play for and about Black gay men in the South

The 12th Annual Women as the Face of AIDS Summit proves that women are resilient, fierce and wise.

Two large studies have found that the two-drug combination of Tivicay and Edurant works as well as standard three- or four-ARV regimens.

“As Much As I Can” is part of the Accelerate! initiative. Tickets are free!

Structural, social and health barriers are challenging the Black gay and bisexual men at the center of the HIV/AIDS epidemic in the South.

Two large trials switched participants from three- or four-drug combos to a regimen of Tivicay (dolutegravir) and Edurant (rilpivirine).

Who are the top 10 global funders, and where do those millions go? The FCAA’s latest findings will surprise you.

The HIV drug is associated with a high rate of insomnia, dizziness and headache, especially among women and those over 60.

Deborah Waterhouse will lead the global HIV pharma company.

The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).